Kymera Therapeutics (KYMR) Research & Development (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Research & Development of $25.0 million for Q1 2026, down 5.37% year-over-year from $26.4 million in Q1 2025, and down 89.81% quarter-over-quarter from $244.9 million in Q4 2025.
Kymera Therapeutics (KYMR) Research & Development (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Research & Development for 8 consecutive years, with $25.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 5.37% year-over-year to $25.0 million; the TTM figure through Mar 2026 stood at $308.1 million (up 145.09% YoY), while the FY2025 annual figure was $316.6 million, up 272.52% from the prior year.
- Research & Development fell to $25.0 million in Q1 2026 per KYMR's latest filing, from $244.9 million in the prior quarter.
- Across five years, Research & Development topped out at $244.9 million in Q4 2025 and bottomed at -$41.4 million in Q4 2023.
- Historically, Research & Development has averaged $43.6 million across 5 years, with a median of $41.3 million in 2022.
- Annual changes were most pronounced in 2023 — Research & Development slumped 196.01% — and 2025, when it surged 820.67%.
- Kymera Therapeutics' Research & Development stood at $43.1 million in 2022, then plunged by 196.01% to -$41.4 million in 2023, then soared by 164.24% to $26.6 million in 2024, then soared by 820.67% to $244.9 million in 2025, then tumbled by 89.81% to $25.0 million in 2026.
- Business Quant data shows KYMR's Research & Development at $25.0 million in Q1 2026, $244.9 million in Q4 2025, and $22.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 119.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 119.48 Mn |
| Mar 31, 2026 | 24.96 Mn |
| Dec 31, 2025 | 244.93 Mn |
| Sep 30, 2025 | 21.95 Mn |
| Jun 30, 2025 | 16.26 Mn |
| Mar 31, 2025 | 26.38 Mn |
| Dec 31, 2024 | 26.60 Mn |
| Sep 30, 2024 | 60.41 Mn |
| Jun 30, 2024 | 12.32 Mn |
| Mar 31, 2024 | 48.82 Mn |
| Dec 31, 2023 | -41.41 Mn |
| Sep 30, 2023 | 48.12 Mn |
| Jun 30, 2023 | 45.77 Mn |
| Mar 31, 2023 | 42.23 Mn |
| Dec 31, 2022 | 43.13 Mn |
| Sep 30, 2022 | 43.88 Mn |
| Jun 30, 2022 | 41.29 Mn |
| Mar 31, 2022 | 35.94 Mn |
| Dec 31, 2021 | 37.53 Mn |
| Sep 30, 2021 | 38.31 Mn |